Drug
Fosigotifator
Fosigotifator: highest development phase Phase 1, developed by AbbVie. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fosigotifator NCT06618118 | Phase 1 | Major Depressive Disorder (MDD) |
| Fosigotifator NCT04948645 | Phase 1 | ALS |
Latest
No recent events.
Follow Fosigotifator on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.